The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Omar Mian discusses: Metastasis-directed Therapy in Prostate Cancer.
Please do read our letter to editor to @JCO_ASCO with regards to the recent publication of the ARANOTE trial. Until when shall we put up with inferior control arms?
Congratulations @abhenilmittal for raising awareness re this important issue.
https://t.co/UrHNIB20tF
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial by @RubenRaychaud et al.
Full article: https://t.co/zxoOGnzpYh
#PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of pts with #mCRPC with homologous recombination DNA repair deficiency @RubenRaychaud@fredhutch. #ASCO24 written coverage by @rksayyid > https://t.co/FY7ssn7URE
💫🌟#Genomic Correlates of Prostate-Specific Membrane Antigen #PSMA
Expression and Response to 177Lu-PSMA-617: A
Retrospective Multicenter Cohort Study🌟💫
@OncoAlert@PGrivasMDPhD@JessicaHawleyMD@RubenRaychaud@LauraGrahamMD@ColinCPritchard@PCFnews@PCF_Science
https://t.co/lobQhDcWxl
🔷️Purpose of the Study
🔹️ To evaluate the association between the mutational profile of metastatic castration-resistant prostate cancer (mCRPC) and the clinical efficacy of treatment with 177Lu-PSMA-617 (LuPSMA).
🔷️Methodology
🔹️ Retrospective multicenter analysis of 126 mCRPC patients who received LuPSMA and had next-generation sequencing (NGS) results.
🔹️ Comparison of treatment response, prostate-specific antigen progression-free survival (PSA PFS), and overall survival (OS) among genetically defined subgroups.
🚨Key Findings
🔹️ Presence of tumor suppressor gene (TSG) mutations was associated with shorter PSA PFS and OS.
🔹️Patients with DNA damage repair (DDR) gene mutations showed improved OS in multivariable analysis.
🔹️ PSMA expression did not show significant differences between DDR-deficient and DDR-proficient cohorts.
🔹️ Patients with ATM mutations demonstrated higher treatment response rates, longer PSA PFS, and better OS.
🔹️ #BRCA2 mutations were not associated with improved clinical outcomes.
🔹️ #CDK12 mutations were associated with poorer responses and shorter PSA PFS.
🔷️Conclusions
🔹️ Variability in clinical outcomes with #LuPSMA can be influenced by the tumor's mutational profile.
🔹️ Prospective studies are warranted to better define the clinical activity of LuPSMA in predetermined genomic subgroups.
🔷️ Limitations
🔹️ Retrospective nature of the study and small sample size of genomic subgroups.
🔹️ Limitations in measuring PSMA expression across multiple sites.
#GenomicMedicine #ProstateCancer #PrecisionOncology #LuPSMA #CancerResearch #mCRPC